The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I expansion study of P-cadherin-targeted 90Y-FF-21101 antibody in advanced chemorefractory colorectal and pancreatic-biliary cancers.
 
Devalingam Mahalingam
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Eisai; Exelixis; Genentech
Research Funding - Merck KGaA; Oncolytics
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape
 
Taofeek K. Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES
Consulting or Advisory Role - Abbvie; Amgen; ARMO BioSciences; AstraZeneca; Bayer; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; EMD Serono; G1 Therapeutics; HERON; Lilly; Lilly; MedImmune; Merck; Novartis; PharmaMar; Sandoz; Seagen; Takeda; Xcovery
Speakers' Bureau - Abbvie
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Corvus Pharmaceuticals; Fujifilm (Inst); G1 Therapeutics (Inst); Incyte (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst); United Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Other Relationship - EMD Serono; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical
 
Susanna Varkey Ulahannan
Consulting or Advisory Role - Array BioPharma; Bayer; Eisai; Exelixis; Incyte; Syros Pharmaceuticals
Research Funding - Abbvie (Inst); ArQule (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); evelo biosciences (Inst); G1 Therapeutics (Inst); Incyte (Inst); Klus Pharma (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst)
 
Debra L. Richardson
Consulting or Advisory Role - AstraZeneca; Bayer; Deciphera; Foundation Medicine; Genentech/Roche; Ipsen; Mersana; Tesaro
Research Funding - Aravive (Inst); ArQule (Inst); AstraZeneca (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Harpoon therapeutics (Inst); Hookipa Biotech (Inst); Innovent Biologics (Inst); Karyopharm Therapeutics (Inst); Lycera (Inst); Merck (Inst); Mersana (Inst); Roche (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Agenus; Karyopharm Therapeutics; Merck; Roche; Tesaro
 
Aparna Kalyan
Consulting or Advisory Role - BMSi; Exelixis; Incyte; Ipsen; QED Therapeutics
Speakers' Bureau - Exelixis
Research Funding - BMSi
 
Mary Frances Mulcahy
Research Funding - BTG
 
Catherine A. Wheeler
Leadership - Targovax
Stock and Other Ownership Interests - Exelixis; Exelixis; Exelixis; Targovax
Consulting or Advisory Role - Akrevia Therapeutics; Alacrita; CUE Biopharma; Dynamo Therapeutics; Exelixis; Fuji Pharma; Polyphor; Red Oak Medicines; Windmil
Travel, Accommodations, Expenses - Fuji Pharma; Targovax
 
Satoshi Matsushima
Employment - Fujifilm
 
Takeaki Suzuki
Employment - Fujifilm
 
Ruth Ann Subach
Employment - Fujifilm
Stock and Other Ownership Interests - Pfizer; Trevena
Consulting or Advisory Role - Fujifilm; Palladio Biosciences
Travel, Accommodations, Expenses - Fujifilm; Palladio Biosciences
 
Mary Johansen
Employment - InPharma
Stock and Other Ownership Interests - Reata Pharmaceuticals (I)
Consulting or Advisory Role - Fujifilm; Fujifilm (I)
Patents, Royalties, Other Intellectual Property - M D Anderson (I)
 
Timothy Madden
Employment - Fujifilm; Fujifilm (I)
Stock and Other Ownership Interests - Reata Pharmaceuticals
Patents, Royalties, Other Intellectual Property - 60 patents held from my previous work as a faculty member at the University of Texas MD Anderson Cancer Center
Travel, Accommodations, Expenses - Fuji Pharma (I); Fujifilm
 
Kin Cheung
Employment - Fujifilm
Consulting or Advisory Role - Fujifilm
Research Funding - Fujifilm
 
David S. Wages
Stock and Other Ownership Interests - iSpecimen
Consulting or Advisory Role - Acerta Pharma/AstraZeneca; Fujifilm; IQvia; Salarius Pharmaceuticals